Headlines about Foamix Pharmaceuticals (NASDAQ:FOMX) have been trending somewhat positive on Monday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Foamix Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.7787207359752 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Foamix Pharmaceuticals (NASDAQ:FOMX) traded up $0.24 on Monday, hitting $5.59. 90,800 shares of the stock traded hands, compared to its average volume of 166,990. Foamix Pharmaceuticals has a one year low of $4.03 and a one year high of $11.27.

FOMX has been the subject of a number of research reports. Credit Suisse Group reissued a “buy” rating and set a $9.00 target price on shares of Foamix Pharmaceuticals in a research note on Wednesday, July 19th. HC Wainwright initiated coverage on Foamix Pharmaceuticals in a research note on Thursday, August 24th. They set a “buy” rating and a $12.00 target price for the company. Finally, Zacks Investment Research cut Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd.

COPYRIGHT VIOLATION WARNING: “Foamix Pharmaceuticals (FOMX) Receiving Somewhat Favorable Press Coverage, Accern Reports” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.watchlistnews.com/foamix-pharmaceuticals-fomx-receiving-somewhat-favorable-press-coverage-accern-reports/1701219.html.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Insider Buying and Selling by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.